Multi-Cancer Panel Test code: 01101 • 71 genes

Multi-Cancer Panel Test code: 01101 • 71 genes
$0.00

Multi-Cancer Panel             71 genes

This panel analyzes genes associated primarily with adult-onset, non-syndromic hereditary cancer predispositionacross multiple major organ systems. The conditions evaluated may include hereditary cancer risks involving, but not limited to:

  • Breast

  • Gynecologic: ovarian and uterine/endometrial

  • Gastrointestinal: colorectal, gastric, and pancreatic

  • Endocrine: thyroid, parathyroid, pituitary, and adrenal glands

  • Genitourinary: renal/urinary tract and prostate

  • Skin: melanoma and basal cell carcinoma

  • Brain and nervous system

Hereditary cancers can have significant genetic heterogeneity, meaning that similar cancer types or clinical presentations may be associated with changes in different genes. As a result, personal and family history or clinical characteristics alone may not always be sufficient to identify the underlying genetic cause. Broad panel testing allows for an efficient evaluation of multiple potential genes based on a single clinical indication.

Genetic testing may provide valuable information by helping to:

  • Confirm or clarify a clinical diagnosis

  • Identify an inherited predisposition to certain cancers

  • Assess hereditary cancer risk

  • Help inform cancer screening and surveillance strategies

  • Support earlier detection of cancer or related symptoms

  • Help assess disease prognosis and progression

  • Inform family planning and genetic counseling

  • Identify potentially affected relatives who may benefit from genetic testing

  • Support consideration for relevant clinical trials

Some genes included in this panel may also be associated with additional medical conditions unrelated to the hereditary cancers evaluated by this test. These additional conditions are not included among the disorders specifically assessed by the panel.

Important Testing Information:
This panel is specifically designed to identify heritable germline genetic variants. It is not intended to detect somatic mutations in tumor tissue and should not be used as a substitute for tumor-based somatic testing.